

3
4 **Determination of digoxin in serum samples using a flow flow-**
5 **through fluorosensor based on a molecularly imprinted**
6 **polymer**

7
8 **Gema Paniagua González, Pilar Fernández Hernando*, J. S. Durand Alegría**

9 *Departamento de Ciencias Analíticas, Facultad de Ciencias, Universidad Nacional de*
10 *Educación a Distancia (UNED), 28040 Madrid (Spain).*

11
12 *Corresponding author. Phone: 0034(91)-3987284; Fax: 0034(91)-3988379. E-mail:
13 pfhernando@ccia.uned.es.

14
15
16 **Abstract**

17 This work describes the development of a competitive flow-through FIA assay
18 for digoxin using a molecularly imprinted polymer (MIP) as the recognition phase. In
19 previous work, a number of non-covalent imprinted polymers were synthesised by
20 “bulk” polymerisation. The digoxin binding and elution characteristics of these MIPs
21 were then evaluated to obtain a highly selective material for integration into a sensor.
22 The optimum MIP was synthesised by photo-initiated polymerisation of a mixture
23 containing digoxin, MAA, EDGMA and AIBN in acetonitrile. The bulk polymer was
24 ground and sieved and the template removed by soxhlet extraction in MeOH/ACN. The
25 MIP was packed into a flow cell and placed in a spectrofluorimeter to integrate the
26 reaction and detection systems. The physical and chemical variables involved in digoxin
27 determination by the sensor (nature and concentration of solution, flow rates, etc.) were
28 optimised. Binding with the non-imprinted polymer (NIP) was also analysed. The new
29 fluorosensor showed high selectivity and sensitivity, a detection limit of $1.7 \times 10^{-2} \mu\text{g L}^{-1}$,
30 and high reproducibility (RSD of 1.03% and 1.77% for concentrations of $1.0 \times 10^{-3} \mu\text{g L}^{-1}$
31 and $4.0 \times 10^{-3} \text{mg L}^{-1}$ respectively). Selectivity was tested by determining the cross-

32 reactivity of several compounds with structures analogous to digoxin. Under the assay
33 conditions used, in which the potential interfering compounds were in concentrations
34 100 times higher than that of the analyte, no interference was recorded. The proposed
35 fluorosensor was successfully used to determine digoxin concentration of human serum
36 samples.

37

38 *Keywords:* Digoxin; Molecular imprinting; Fluorosensor; Human serum analysis

39

40 **1. Introduction**

41 The use of molecular imprinting in the design of new drug delivery systems and
42 devices has attracted much attention in recent years. Molecularly imprinted polymers
43 (MIPs) combine highly selective molecular recognition properties (comparable to those
44 of biological systems) with characteristics such as physical robustness and good
45 thermal, chemical and mechanical stability. This renders them particularly suitable for
46 use as recognition elements in sensor technology (D'Agostino et al., 2006; Huang et al.,
47 2007). Further, these materials can be employed in aqueous and non-aqueous media and
48 can be manufactured in different configurations (e.g., as blocks, beads, microspheres,
49 thin-films, filaments or microstructures) to facilitate their integration into sensor design
50 (Lakshmi et al., 2006; Breton et al., 2006). MIPs can also be used in chromatographic
51 separation (Watabe et. al., 2005), as selective adsorbents for cleaning samples (Chapuis
52 et. al., 2006), in solid-phase extraction (Hu et. al., 2005; Baggiani et. al., 2007), and as
53 catalysts (Vokmann and Brüggermann, 2006). Molecular imprinting is now an
54 established technique for the production of molecular recognition materials with
55 predetermined affinities for analytes such as amino acids (Li and Husson, 2006),
56 proteins (Bossi et. al., 2007), carbohydrates (Furqan and Hansen, 2007), drug

57 compounds (Suede et. al., 2006), pesticides (Wei et. al., 2006), steroids, corticosteroids
58 (Sun et. al., 2006), and metal ions (Kidschy and Alocilja, 2005).

59 Digoxin is a glycoside used in the treatment of congestive heart failure; in fact it
60 has been used for this for over 200 years and is still one of the most widely prescribed
61 heart failure drugs. Strict control of digoxin therapy is necessary, however, since there is
62 a thin line separating therapeutic and toxic levels ($0.05\text{-}0.2 \mu\text{g l}^{-1}$); sensitive and
63 selective detection techniques are therefore required. This paper describes a flow-
64 injection optical sensor for digoxin that combines sensor technology with a new
65 generation of molecularly imprinted synthetic receptors. Preliminary work on the
66 composition and synthesis conditions of this MIP has been reported (Paniagua et. al.,
67 2006); this allowed the most suitable MIP for the new fluorosensor for digoxin to be
68 chosen. MIPs were synthesised under different conditions, i.e., changing the functional
69 monomer employed (methacrylic acid or 2-vinylpyridine) as well as the porogen
70 (acetonitrile or dichloromethane). The polymerisation process was studied under UV
71 light (365 nm) or in a thermostat-controlled waterbath (60°C) for 8 to 14 h. The binding
72 and elution solutions, the concentration of the labelled antigen solution and the flow rate
73 were all optimised. The binding of digoxin to the non-imprinted polymer (NIP) was
74 also examined under optimum conditions. The proposed fluorosensor was highly
75 selective and sensitive and provided highly reproducible results. The proposed
76 fluorosensor was successfully used to determine the digoxin concentration of human
77 serum samples.

78

79

80

81

82 **2. Material and Methods**

83 *2.1. Reagents*

84 Ethylene glycol dimethacrylate (EDMA) and methacrylic acid (MAA) were
85 purchased from Merck (Darmstadt, Germany), 2-2'-azobisisobutyronitrile (AIBN) from
86 Fluka (Buchs, Switzerland), and digoxin (95%), morphine, heroine, codeine, tebaine,
87 pentazocine and narcotine from Sigma Aldrich (Madrid, Spain). Digoxin labelled with
88 fluorescein isothiocyanate (FITC) ($10 \mu\text{mol l}^{-1}$) was obtained from MicroPharm
89 (Newcastle, Carmarthenshire, UK). Acetonitrile (ACN) and methanol (HPLC grade)
90 were supplied by Scharlau (Barcelona, Spain). Phosphate buffer solution (PBS, pH=7.5)
91 (NaCl 0.1 mM; KH_2PO_4 1.4 mM; KCl 2.7 mM; NaH_2PO_4 8 mM; MgCl_2 21.3 mM),
92 anhydrous sodium carbonate and sodium dodecylsulphate (SDS) were obtained from
93 Merck (Darmstadt, Germany). Deionised water ($18.3 \text{ M}\Omega \text{ cm}$) used in the preparation
94 of aqueous solutions was obtained using a Milli-Q water system (Millipore Ibérica,
95 Madrid, Spain).

96

97 *2.2. Instrumentation*

98 Fluorescence intensity was measured with a Perkin-Elmer LS-5
99 spectrofluorimeter equipped with a 100 μl Hellma (Jamaica, NY, USA) flow cell
100 (optical path 3 mm) in conjunction with an AAT computer. The flow-injection system
101 consisted of a Gilson Minipulse-2 peristaltic pump and an Omnifit six-way injection
102 valve. PTF tubes (0.5 mm i.d) were used to build the manifold. The pH was measured
103 using a Metrohm 654 pH meter. An ultraviolet lamp (Vilber Lourmat CN-6T) was used
104 to induce polymerisation. The morphology of the polymer was characterised using a
105 Jeol JSM-6400 scanning electron microscope (SEM). The surface area of the imprinted

106 polymer was characterized using a Micromeritics ASAP 2000 apparatus (Norcross,
107 USA).

108

109 *2.3. Procedures*

110 *Preparation of the molecularly imprinted polymer*

111 In preliminary work (Paniagua et. al., 2006), a number of polymers were
112 prepared by bulk polymerisation under different synthesis conditions in order to select
113 that with the best digoxin-recognition characteristics. Several functional monomers
114 (methacrylic acid or 2-vinylpyridine) and different types of porogen (ACN, chloroform
115 or dichloromethane) were tested. The best polymerisation procedure (either employing
116 a UV source or a thermostat-controlled waterbath) and extraction process (soxhlet or
117 microwave extraction) were also determined. The surface morphology of the polymers
118 was analysed by SEM, and the binding affinity of the different digoxin-MIPs evaluated
119 by equilibrium binding experiments. The molecular ratio of the optimum polymer was
120 (10^{-3} :1:5) digoxin:MAA:EDMA. The fluorosensor was equipped with this polymer,
121 which was prepared in a glass tube by the bulk polymerisation method using a mixture
122 of the template molecule (2.0×10^{-3} mmol), methacrylic acid (2.0 mmol), ethylene glycol
123 dimethacrylate (10.0 mmol), 2-2'-azobisisobutyronitrile (6.0×10^{-2} mmol), and 10 ml of
124 ACN as a porogen. The pre-polymerisation mixture was degassed with nitrogen for 5-
125 10 min. A control polymer were prepared using the same composition but in the
126 absence of the template. The glass tube was then exposed to the UV source (λ /nm 365
127 nm) at 10°C for 24 h. After polymerisation, the polymer block was removed from the
128 glass tube and was manually ground in a mortar and sieved to a particle size of 355-600
129 μ m. The template was extracted by the Soxhlet system with MeOH:ACN (50:50, v/v)
130 over a period of 20 h.

131 *Preparation of the fluorosensor*

132 Figure 1 shows the fluorosensor apparatus. The reactor was a flow-through cell
133 (100 μl) packed with the sensitive phase (digoxin-MIP); this was placed in the
134 spectrofluorimeter, thus integrating the reaction and detection systems. The flow stream
135 was generated by an upstream peristaltic pump. The samples were introduced into the
136 system by a six-way valve equipped with a 150 μl sample loop.

137

138 *Sample preparation*

139 Digoxin-containing serum samples were supplied by the Puerta de Hierro
140 Hospital (Madrid). These were stored at 4°C. Sample aliquots of 650 μl were added to
141 900 μl of ACN and centrifuged at 3500 rpm for 30 min to precipitate the proteins.

142 *Competitive assay protocol for the determination of digoxin in serum samples*

143 To determine the digoxin concentration of the serum samples, a heterogeneous
144 fluorescent competitive assay was undertaken in which the digoxin competed with a
145 fluorescent tracer (FITC-digoxin) for recognition sites in the digoxin-MIP. For this,
146 1700 μl of purified serum was mixed with 170 μl of FITC-digoxin (0.2 $\mu\text{mol l}^{-1}$). The
147 competitive calibration curve was obtained using digoxin solutions (1000 μl) at
148 different concentrations (0-4 \times 10⁻³ mg l⁻¹) in ACN. This required a digoxin stock
149 solution (0.5 ppm) be prepared in a mixture of ACN and Na₂CO₃ (0.1 M, pH=8.0)
150 (50:50 v/v). For the preparation of the standard solutions, different aliquots of the 0.5
151 stock solution were added to 100 μl of FITC-digoxin (1:50 in ACN, 0.2 $\mu\text{mol l}^{-1}$), and
152 ACN then added to 1000 μl . 150 μl of corresponding standard were then injected into
153 the carrier solution (ACN) at a flow rate of 0.27 ml min⁻¹. Excess antigens, labelled and
154 unlabelled, were removed by the carrier solution. The fluorescence signal generated was

155 measured *in situ* in the reactor at λ_{em}/nm 517 and λ_{exc}/nm 496. Finally, an elution
156 solution (MeOH/ACN, 90:10) was pumped into the flow cell to regenerate the reactor.

157

158 **3. Results and Discussion**

159 *3.1. Optimisation of experimental conditions and characterisation of the sensor*

160 The sensitivity, selectivity and response time of the fluorescent sensor were
161 determined. The composition of the polymer and its polymerisation conditions were
162 determined in previous work (Paniagua et. al., 2006). The greatest specific binding was
163 achieved with ACN (42%). This solvent showed a very low binding affinity for the
164 control polymer; non-specific binding was 19%. The percentage uptake with the
165 imprinted polymer was 61%. Using this information it was possible to select the
166 polymer best suited to act as the recognition phase in the proposed sensor.

167 The effect of polymerisation on the particle structure of the methacrylic polymer
168 was also examined. The surface area, specific pore volume and average pore diameter
169 of the polymer were obtained by nitrogen sorption porosimetry. The MIP had a specific
170 surface area of $31.844\text{ m}^2\text{ g}^{-1}$ and a specific pore volume of $0.194\text{ cm}^3\text{ g}^{-1}$. The pore size
171 distribution was macropores 50%, mesopores 44.33%, and micropores 5.67%.

172 The study of the binding mechanism and regeneration of the polymer was
173 carried out. The efficacy of the retention process was affected by the carrier solvent, pH,
174 and the flow rate. The amount of labelled digoxin used was optimised in order to obtain
175 good sensitivity and a strong fluorescence signal. For this, 150 μl of digoxin-FITC at
176 different concentrations (0.0075; 0.15; 0.2; 0.3 $\mu\text{mol l}^{-1}$) plus several carrier solvents
177 (ACN, MeOH and aqueous phosphate buffer solution PBS, pH=7.5) were assayed by
178 spectrofluorimetry at λ_{exc}/nm 496 (λ_{em}/nm 517). Figure 2 shows the fluorescence
179 signals obtained using different binding solutions for different concentrations of FITC-

180 digoxin. The effect of the binding solution flow rate was studied in the range 0.1 to 0.6
181 ml min⁻¹. The effect of pH (3-9) was also tested. ACN at pH 9.0 was finally selected as
182 the carrier solution. The optimum flow rate was 0.27 mL min⁻¹. With a slightly higher
183 flow rate (0.3 ml min⁻¹) no improvements were seen; higher flow rates considerably
184 reduced the retention of the polymer. To increase the strength of the fluorescence
185 signals, the tensactive effect of different concentrations (4.0, 6.0, 8.0 and 10.0 mM) of
186 SDS was examined; 100 µl SDS of each concentration were added to 50 ml of ACN.
187 The best fluorosensor response was obtained when working close to the critical micellar
188 concentration (8.1 mM) of SDS; the optimum value was 8.0 mM.

189 To prevent the polymer losing binding capacity, the optimum washing time was
190 determined, and regeneration solutions used to regenerate the reactive phase. The effect
191 of a 30-120 s washing time was studied for a 0.2 µmol l⁻¹ digoxin-FITC solution; the
192 optimum time was 80 s. Shorter times did not allow the polymer to regenerate, thus
193 reducing its binding capacity. Longer times did not improve the process. MeOH:H₂O
194 (70:30, 50:50 and 30:70), MeOH:ACN (90:10), MeOH:ACN:H₂O (80:10:10) and
195 MeOH and H₂O were all tested as regeneration solutions. Figure 3 shows their elution.
196 MeOH:ACN (90:10) provided the best results.

197 A binding assay using NIP as the reactive phase was undertaken under optimum
198 conditions. No digoxin bound to the NIP.

199

200 3.2. Analytical performance

201 To determinate the selectivity of the MIP, cross-reactivity with narcotine,
202 tebaine, heroine, pentazocine, morphine and codeine was examined. For interference
203 studies, competitive calibration curves were plotted, using concentrations of 0-6×10² µg
204 l⁻¹ of digoxin. The ratios between the I₅₀ values determined for digoxin and the

205 potentially interfering substances were calculated. In no case was cross reactivity
206 detected, even when the concentration of the test molecules was 100 times that of the
207 analyte (Fig. 5).

208 A competitive calibration curve was obtained for the working range of $0-4 \times 10^{-3}$
209 mg l^{-1} digoxin and $0.2 \mu\text{mol l}^{-1}$ of FITC-digoxin. The normalized fluorescence signal,
210 %B/Bo (where B is the intensity of fluorescence of the conjugated digoxin at different
211 standard concentrations of digoxin, and Bo that of the blank), was plotted against the
212 digoxin concentration. Figure 4 shows the calibration curve obtained. The curve
213 equation was: $\%B/Bo = 9 \times 10^6 C^2 - 5 \times 10^4 C + 96$ ($n=5$, $r=0.990$). The detection limit (X-
214 2SD) was calculated using five replicates of zero standards and expressed as the least
215 detectable dose (LDD) of digoxin; under optimum conditions this was $1.7 \times 10^{-2} \mu\text{g l}^{-1}$.
216 The relative standard deviations (RSD) of six determinations for 1×10^{-3} and $4 \times 10^{-3} \text{mg l}^{-1}$
217 digoxin were 1.0% and 1.8% respectively; for the serum samples an RSD of <10% was
218 obtained. The total time required for each assay was 400 s. The lifetime of the sensor
219 without loss of sensitivity was approximately 18 months; no special storage conditions
220 were necessary to maintain optimum performance.

221

222 3.3. Sample analysis application

223 Table 1 shows the results of the determination of digoxin in the serum samples
224 obtained using the proposed method and a reference method (MEIA, microparticle
225 immunoenzyme assay, Abbott Laboratories). No significant differences were seen
226 between the values obtained ($p < 0.05$).

227

228

229

230 **4. Conclusions**

231 This paper proposes a new molecularly imprinted fluorescence sensor for
232 determining the concentration of digoxin in serum. Strategies for selecting the best
233 combination of monomers, cross-linkers, solvents and polymerisation conditions for
234 production of the MIP were established. This included determining the best morphology
235 of the MIP and the optimum pore size. The polymer finally chosen showed good
236 digoxin-recognition properties and was sufficiently stable for integration into a flow-
237 through fluorosensor. The imprinted polymer showed good thermal (up to 80°C) and
238 chemical stabilities and can be used over the pH range 3-9; no digoxin bound to the
239 NIP. Cross-reactivity with compounds of similar structures was negligible.
240 Consequently, this fluorosensor is highly sensitive and selective for digoxin. The
241 analysis and regeneration time is very short (about 400 s). When used to determine
242 digoxin concentrations in human serum, the fluorosensor provided satisfactory results.

243

244 **Acknowledgements**

245 The authors thank the Spanish Ministry of Science and Technology for financial
246 support (project CTQ 2006 -15027/PPQ), the Puerta de Hierro Hospital for supplying
247 serum samples and Adrian Burton for correcting the manuscript.

248

249 **References**

- 250 Baggiani, C., Baravalle, P., Giraudi, G., Tozzi, C., 2007. *J. Chromatog. A* 1141, 158-
251 164.
- 252 Bossi, A., Borini, F., Turner, A.P.F., Pilektski, S.A., 2007. *Biosens. Bioelectron.* 22,
253 1131-1137.
- 254 Breton, F., Euzet, P., Piletski, S.A., Giardi, M.T., Rouillon, R., 2006. *Anal. Chim. Acta*
255 569, 50-57.
- 256 Chapuis, F., Mullot, J.U., Pichón, V., Tufall, G., Jennion, M.C., 2006. *J. Chromatog. A*
257 1135, 127-134.
- 258 D'Agostino, G., Alberti, G., Biesuz, R., Pesavento, M., 2006. *Biosens. Bioelectron.* 22,
259 145-152.
- 260 Furqan, M. F., Hansen, D.E., 2007. *Biorg. Medic. Chem. Lett.* 17, 235-238.
- 261 Huang, C.Y., Syu, H.J., Chang, Y.S., Chuan, T., Liu, B.D., 2007. *Biosens. Bioelectron.*
262 22, 1694-1699.
- 263 Hu, S.G., Li, L., He, X.W., 2005. *J. Chromatog. A* 1062, 31-37.
- 264 Kidschy, L.M., Alocilja, E.C., 2005. *Biosens. Bioelectron.* 20, 2163-2167.
- 265 Lakshmi, D., Prasad, B. ., Sharma, P.S.S., 2006. *Talanta* 70, 272-280.
- 266 Li, X., Husson, S.M., 2006. *Biosens. Bioelectron.* 22, 336-348.
- 267 Paniagua, G., Fernández, P., Durand, J.S., 2006. *Anal. Chim. Acta* 557, 179-183.
- 268 Suede, R., Seechamnaturakit, V., Canyuk, B., Ovatalarnporn, C., Martin, G. P., 2006.
269 *J. Chromatogr. A* 1114, 239-249.
- 270 Sun, H.W., Qiao, F.X., Liu, G.Y., 2006. *J. Chromatogr. A* 1134, 194-200.
- 271 Vokmann, A., Brüggermann, O., 2006. *React. Funct. Polym.* 66, 1725-1733.
- 272 Watabe, Y., Hosoya, H., Tanaka, N., Kerbo, Y., Kondo, T., Morita, M., 2005. *J.*
273 *Chromatogr. A* 1073, 363-370.

274 Wei, S., Molinelli A., Mizaikoff. B., 2006. Biosen. Bioelectron. 21, 1943-1951.

275

276

277

278 **FIGURE LEGENDS**

279

280 Fig. 1. The flow-through sensor system.

281

282 Fig. 2. Binding studies on MIP for different concentrations of digoxin-FITC and
283 solvents. Carrier solutions: ACN, MeOH, PBS (10 mM, pH= 7.5). Flow rate: 0.27 ml
284 min⁻¹. Digoxin-FITC concentrations (7.5×10^{-3} ; 0.15; 0.2; 0.3 $\mu\text{mol l}^{-1}$).

285

286 Fig .3. Elution percentages for different solutions. Carrier solution: ACN (pH= 9; SDS
287 8mM). Flow rate: 0.27 ml min⁻¹, [digoxin-FITC]= 0.2 $\mu\text{mol l}^{-1}$.

288

289 Fig. 4. Calibration curve for the optimum sensor, obtained by plotting the normalized
290 signal against the digoxin concentration.

291

292 Fig. 5. Calibration curves obtained with the optimum fluorosensor for digoxin and
293 structurally analogous compounds.

294

295 **TABLES**

296 Table 1

297 Results of human serum samples analysis

Sample	Fluorosensor	Reference method
	$10^{-4} (X \pm SD)/\text{ng } \mu\text{l}^{-1}$	$10^{-4} (X \pm SD)/\text{ng } \mu\text{l}^{-1}$
1	(7.6 ± 0.8)	(8.0 ± 0.3)
2	(2.5 ± 0.2)	(3.0 ± 0.2)
3	(21.0 ± 2.1)	(24.2 ± 1.3)
4	(9.1 ± 0.6)	(9.0 ± 0.3)
5	(15.2 ± 0.9)	(19.0 ± 2.1)
6	(8.4 ± 0.7)	(8.0 ± 0.4)

298

299

300 **FIGURES:**

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324




Fig.1

325




Fig.2

326

327

328

329

330

331

332

333

334

335


336

337

338

339

340



341
342
343

Fig.3

344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367




Fig.4




Fig. 5

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382